Stanislav ŽIARAN1, Štefan HARSÁNYI2, Katarína BEVÍZOVÁ3, Zuzana VARCHULOVÁ NOVÁKOVÁ2, Peter BUJDÁK1, Štefan GALBAVÝ4, Daniel BöHMER2, Ľuboš DANIŠOVIČ2

1Urologická klinika, Lekárska fakulta, Univerzita Komenského v Bratislave, prednosta Dr.h.c. prof. MUDr. Ján Breza, DrSc., MHA, MPH
2Ústav lekárskej biológie, genetiky a klinickej genetiky, Lekárska fakulta, Univerzita Komenského v Bratislave, prednosta doc. MUDr. Daniel Böhmer, PhD.
3Anatomický ústav, Lekárska fakulta, Univerzita Komenského v Bratislave, prednosta doc. MUDr. Eliška Kubíková, PhD.
4Ústav súdneho lekárstva, Lekárska fakulta, Univerzita Komenského v Bratislave, prednosta doc. MUDr. Jozef Šidlo, CSc., MPH

Summary
Urothelial bladder cancer is a relatively frequent malignant disease with variable incidence and clinical behavior that often has high recurrence rates. Incidence varies with age and gender. In our work, we analysed tumor tissues of 224 patients with pTa and pT1 urinary bladder cancer, in which we investigated the prognostic value of p53, Ki-67 and E-cadherin markers. Methods used in the examination were histological analysis, immunohistochemistry and statistical analysis. We performed statistical analysis of cancer-specific survival, progression-free survival, and recurrence-free survival. In conclusion of our study Ki-67 and E-cadherin demonstrated highest potential in prediction of pT1 urinary bladder cancer. Our data also indicates that Ki-67 can be used as an independent marker of tumor progression in pTa and pT1 urinary bladder cancer.
Key words: cancer, urothelium, bladder, p53, Ki69, E-cadherin.

Lek Obz (Med Horizon), 2020, 69(2): 38 – 43